Form 4: Amgen EVP Jonathan P. Graham Reports Acquisition of Stock and Stock Options

Jonathan P. Graham, EVP & General Counsel & Secretary of Amgen Inc., reports the acquisition of common stock and stock options.

Summary

• On May 6, 2025, Jonathan P. Graham, EVP & General Counsel & Secretary of Amgen Inc., acquired 3,180 shares of common stock.
• These shares were acquired at a price of $0.
• Following the transaction, Graham directly owns 33,517 shares of Amgen common stock.
• Graham also acquired 20,554 non-qualified stock options with an exercise price of $270.44, exercisable beginning May 6, 2026.
• The stock options expire on May 6, 2035.
• The restricted stock units (RSUs) vest in four equal annual installments of 25% each, commencing on 5/6/2026.
• Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock and option acquisitions by an executive, which is a common practice. It doesn't inherently indicate positive or negative sentiment, but rather reflects standard compensation practices.

Positives

• The acquisition of stock and stock options by a high-ranking executive could be interpreted as a sign of confidence in the company's future performance.

Future Outlook

The acquired stock options vest and are exercisable in four equal annual installments of 25% each, commencing on 5/6/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

Industry Context

Executive stock ownership is a common practice in publicly traded companies like Amgen to align management's interests with those of shareholders. These transactions are routinely disclosed through SEC filings.

Comparison to Industry Standards

• Stock option grants and RSU awards are standard compensation practices for executives in the biotechnology industry, including companies like Gilead Sciences, Biogen, and Regeneron.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term performance and retention.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of executive confidence in the company.

Key Dates

Keywords

Amgen, Jonathan P. Graham, stock options, common stock, acquisition, RSUs, Form 4, insider trading